As-To The Moon - Tiger Brokers Online Investing Community - To The Moon

4
Comment
Favorite

As

AstraZeneca Says Key Lung Cancer Drug Improved Survival

Company describes data as a breakthrough for patientsImfinzi is already approved for several other indicationsAstraZeneca Plc’s lung cancer drug improved survival in patients with a highly aggressive

AstraZeneca Says Key Lung Cancer Drug Improved Survival

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

4

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":292034013519992,"tweetId":"292034013519992","gmtCreate":1712323282579,"gmtModify":1712323286307,"author":{"id":4088146696976370,"idStr":"4088146696976370","authorId":4088146696976370,"authorIdStr":"4088146696976370","name":"bengkoon","avatar":"https://static.tigerbbs.com/ee8ec0fb6d2ba6a8495d1b92f45a46fe","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.16%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":30,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>As</p></body></html>","htmlText":"<html><head></head><body><p>As</p></body></html>","text":"As","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/292034013519992","repostId":1107408900,"repostType":2,"repost":{"id":"1107408900","pubTimestamp":1712322762,"share":"https://www.laohu8.com/m/news/1107408900?lang=&edition=full","pubTime":"2024-04-05 21:12","market":"us","language":"en","title":"AstraZeneca Says Key Lung Cancer Drug Improved Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=1107408900","media":"Bloomberg","summary":"Company describes data as a breakthrough for patientsImfinzi is already approved for several other indicationsAstraZeneca Plc’s lung cancer drug improved survival in patients with a highly aggressive ","content":"<html><head></head><body><ul style=\"\"><li><p>Company describes data as a breakthrough for patients</p></li><li><p>Imfinzi is already approved for several other indications</p></li></ul><p>AstraZeneca Plc’s lung cancer drug improved survival in patients with a highly aggressive form of the disease, becoming the first immunotherapy to help these patients live longer, the company said.</p><p style=\"text-align: start;\">Imfinzi showed statistically significant and clinically meaningful improvement in both slowing the progression of the disease and overall survival, according to initial results from an advanced study.</p><p style=\"text-align: start;\">Limited-stage small cell lung cancer typically affects one lung or one side of the chest and has a very poor prognosis, with just 15% to 30% of patients living for five years after their diagnosis.</p><p style=\"text-align: start;\">This is the first trial to mark a “breakthrough for patients with this devastating disease,” said the principal investigator in the study Suresh Senan. He said many patients face disease recurrence and, until now, the standard of care had remained unchanged for decades.</p><p style=\"text-align: start;\">Lung cancer is the leading cause of cancer death among men and women, accounting for about 20% of all cancer deaths.</p><p>Imfinzi is already approved for several other indications including non-small cell lung cancer that is locally advanced and cannot be removed by surgery. It is Astra’s second best-selling cancer drug after Tagrisso.</p><p style=\"text-align: start;\">Chief Executive Officer Pascal Soriot is reaping the benefits of his bet on cancer, with Astra having invested heavily in this area, including through collaborations with companies such as Daiichi Sankyo Co.</p><p style=\"text-align: start;\">The trial results follow “a raft of positive readouts and approvals for Imfinzi” that have stimulated a strong uptick in sales, said <u>Shore Capital</u>’s Sean Conroy. However, he said given that forecasts had already worked in Imfinzi’s uses in lung cancer “we don’t anticipate any significant upgrades based on these data alone.”</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Says Key Lung Cancer Drug Improved Survival</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Says Key Lung Cancer Drug Improved Survival\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-05 21:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2024-04-05/astrazeneca-says-key-lung-cancer-drug-improved-survival?srnd=homepage-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Company describes data as a breakthrough for patientsImfinzi is already approved for several other indicationsAstraZeneca Plc’s lung cancer drug improved survival in patients with a highly aggressive ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2024-04-05/astrazeneca-says-key-lung-cancer-drug-improved-survival?srnd=homepage-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://www.bloomberg.com/news/articles/2024-04-05/astrazeneca-says-key-lung-cancer-drug-improved-survival?srnd=homepage-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107408900","content_text":"Company describes data as a breakthrough for patientsImfinzi is already approved for several other indicationsAstraZeneca Plc’s lung cancer drug improved survival in patients with a highly aggressive form of the disease, becoming the first immunotherapy to help these patients live longer, the company said.Imfinzi showed statistically significant and clinically meaningful improvement in both slowing the progression of the disease and overall survival, according to initial results from an advanced study.Limited-stage small cell lung cancer typically affects one lung or one side of the chest and has a very poor prognosis, with just 15% to 30% of patients living for five years after their diagnosis.This is the first trial to mark a “breakthrough for patients with this devastating disease,” said the principal investigator in the study Suresh Senan. He said many patients face disease recurrence and, until now, the standard of care had remained unchanged for decades.Lung cancer is the leading cause of cancer death among men and women, accounting for about 20% of all cancer deaths.Imfinzi is already approved for several other indications including non-small cell lung cancer that is locally advanced and cannot be removed by surgery. It is Astra’s second best-selling cancer drug after Tagrisso.Chief Executive Officer Pascal Soriot is reaping the benefits of his bet on cancer, with Astra having invested heavily in this area, including through collaborations with companies such as Daiichi Sankyo Co.The trial results follow “a raft of positive readouts and approvals for Imfinzi” that have stimulated a strong uptick in sales, said Shore Capital’s Sean Conroy. However, he said given that forecasts had already worked in Imfinzi’s uses in lung cancer “we don’t anticipate any significant upgrades based on these data alone.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":421,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}